InflaRx N.V.

Analysis for Ticker: IFRX

InflaRx NV is a biotechnology company in Jena, Germany, that claims to develop medicine for severe inflammatory diseases by targeting specific proteins in the blood. The reality is that the company operates as a wealth transfer mechanism where capital is consumed to sustain a corporate structure that produces almost nothing. In 2025, the business generated exactly 29.331€ in revenue. To make that tiny amount of money, it spent 45,6€ million. This is like a business that spends forty-five thousand dollars on wood and nails to build a birdhouse but only sells it for twenty-nine dollars. The math is a disaster because the company loses money nearly two thousand times faster than it brings it in, resulting in an accumulated deficit of 377,8€ million. The current cycle of extraction began on 10/11/2025, when the company promoted clinical data for an oral drug called izicopan. They used a very small group of thirty-one patients and cut the data into tiny pieces to make it look like a success. They left out two patients in one group and one in another to keep the results favorable. They then compared these three dozen people to historical results from other drugs, which is a legal way to create excitement for investors without actually proving the drug is better in a real head-to-head test. Behind this scientific story, the company filed legal documents that tied the news to their ability to sell more stock.